SGLT2 Inhibitors: Selecting the Right Agent Within the Class

The Five Agents and Where They Overlap

Each SGLT2 inhibitor blocks the sodium-glucose co-transporter 2 in the proximal tubule, producing glycosuria, mild natriuresis, and osmotic diuresis. The pharmacologic mechanism is shared. The clinical evidence is not.

FDA-Approved Indications at a Glance

Empagliflozin (Jardiance) holds approvals for type 2 diabetes mellitus (T2DM), heart failure (HF) across ejection fraction spectrum, and chronic kidney disease (CKD) at risk of progression 1. Dapagliflozin (Farxiga) mirrors that triad with its own independent trial portfolio 2. Canagliflozin (Invokance) is approved for T2DM and for reducing the risk of end-stage kidney disease in adults with T2DM and diabetic nephropathy with albuminuria 3. Ertugliflozin (Steglatro) carries only a T2DM indication. Sotagliflozin (Inpefa), a dual SGLT1/2 inhibitor, is approved specifically for reducing cardiovascular death and heart failure hospitalization in adults with HF or T2DM with cardiovascular risk factors 4.

Selectivity and Pharmacokinetic Differences

SGLT2 selectivity varies across the class. Empagliflozin has the highest SGLT2-to-SGLT1 selectivity ratio (approximately 2,500-fold), while canagliflozin has a lower ratio (roughly 250-fold), which may explain its modest postprandial glucose-lowering effect through intestinal SGLT1 blockade 5. Sotagliflozin is deliberately non-selective (approximately 20-fold), producing clinically meaningful SGLT1 inhibition in the gut. Half-lives range from 10 to 13 hours for most agents, allowing once-daily dosing for the entire class.

Matching Agent to Indication

The decision tree starts with the primary reason for prescribing. A patient with isolated T2DM and no established cardiovascular or kidney disease presents a different calculus than one with HFpEF and an eGFR of 35.

Type 2 Diabetes Without Established CV or Kidney Disease

For glycemic control alone, all six agents reduce A1C by 0.5% to 0.9% depending on baseline and background therapy 6. The 2024 ADA Standards of Care state: "For patients with type 2 diabetes and established or high risk for atherosclerotic cardiovascular disease, heart failure, and/or chronic kidney disease, treatment selection should include an SGLT2 inhibitor with demonstrated cardiovascular or kidney benefit independent of A1C" 7. When the sole target is glucose, formulary cost and insurance tier often determine the pick. Ertugliflozin and bexagliflozin may be available at lower copays but lack outcome data beyond glycemic endpoints.

Heart Failure (Reduced and Preserved Ejection Fraction)

Empagliflozin and dapagliflozin are the two agents with strong HF data across the ejection fraction spectrum. DAPA-HF (N=4,744) demonstrated a 26% relative risk reduction in the composite of worsening HF or cardiovascular death with dapagliflozin versus placebo in HFrEF (HR 0.74, 95% CI 0.65-0.85) 2. EMPEROR-Reduced (N=3,730) showed a 25% reduction in the same composite with empagliflozin (HR 0.75, 95% CI 0.65-0.86) 8.

For HFpEF, EMPEROR-Preserved (N=5,988) and DELIVER (N=6,263) extended the class effect. DELIVER showed dapagliflozin reduced the primary composite by 18% (HR 0.82, 95% CI 0.73-0.92) in patients with LVEF >40% 9.

Sotagliflozin presents a differentiated option for HF patients with concurrent T2DM. The SOLOIST-WHF trial (N=1,222) enrolled patients recently hospitalized for worsening HF with T2DM and showed a 33% reduction in cardiovascular death and HF events (HR 0.67, 95% CI 0.52-0.85) 4. Its dual SGLT1/2 mechanism may offer additional postprandial hemodynamic benefits, though the trial was stopped early due to loss of funding during the COVID-19 pandemic.

Chronic Kidney Disease

Dapagliflozin and empagliflozin both carry CKD indications. DAPA-CKD (N=4,304) enrolled patients with an eGFR of 25 to 75 mL/min/1.73 m² and a urinary albumin-to-creatinine ratio of 200 to 5,000 mg/g, with or without diabetes. The trial was stopped early for efficacy: dapagliflozin reduced the primary composite of sustained eGFR decline ≥50%, end-stage kidney disease, or renal/cardiovascular death by 39% (HR 0.61, 95% CI 0.51-0.72) 10. EMPA-KIDNEY (N=6,609) extended these findings to a broader population, including patients without significant albuminuria, showing a 28% reduction in kidney disease progression or cardiovascular death (HR 0.72, 95% CI 0.64-0.82) 11.

Canagliflozin's CREDENCE trial (N=4,401) was the first dedicated renal outcome trial in the class and demonstrated a 30% reduction in the primary renal composite (HR 0.70, 95% CI 0.59-0.82), but it enrolled only patients with T2DM 3. For CKD without diabetes, dapagliflozin and empagliflozin have the data.

The 2024 KDIGO guideline recommends: "We suggest SGLT2 inhibitors for adults with CKD who have an eGFR ≥20 mL/min/1.73 m²" 12.

Safety Signals That Differentiate Agents

The class shares a baseline safety profile: genital mycotic infections (5-10% of women, 3-5% of men), volume depletion in older adults on loop diuretics, and euglycemic diabetic ketoacidosis (eDKA), which occurs at a rate of approximately 0.1% per year in T2DM and requires vigilance in insulin-deficient states 13. The differentiating signals fall on specific agents.

Canagliflozin and Amputation Risk

The CANVAS program (N=10,142) identified a nearly twofold increase in lower-limb amputations with canagliflozin versus placebo (6.3 vs. 3.4 per 1,000 patient-years, HR 1.97, 95% CI 1.41-2.75) 14. The FDA initially added a boxed warning, later downgraded to a standard warning after post-marketing surveillance did not consistently replicate the signal. CREDENCE did not show a statistically significant increase. Still, many prescribers avoid canagliflozin in patients with peripheral arterial disease, prior amputation, or active foot ulceration.

Fournier Gangrene and the Entire Class

The FDA issued a warning in 2018 for necrotizing fasciitis of the perineum (Fournier gangrene) across all SGLT2 inhibitors. The absolute incidence is exceedingly rare (55 cases in the FAERS database over a 5-year period across millions of prescriptions) 15. This signal has not differentiated one agent from another.

Bone Fracture Considerations

Canagliflozin was associated with a higher fracture rate in the CANVAS program (15.4 vs. 11.9 per 1,000 patient-years) 14. Dapagliflozin and empagliflozin have not shown this signal in their respective outcome trials. In patients with osteoporosis risk factors, this may tip the selection away from canagliflozin.

Renal Thresholds and Dose Adjustments

The minimum eGFR at which each agent can be initiated or continued varies, and these thresholds have shifted as renal and HF outcome data accumulated.

Initiation Thresholds by Agent

Empagliflozin can be initiated for CKD or HF at eGFR ≥20 mL/min/1.73 m² per the updated label. Dapagliflozin similarly permits initiation at eGFR ≥25 for CKD (per the DAPA-CKD entry criteria) and ≥20 in some HF contexts. Canagliflozin should not be initiated below eGFR 30 for the diabetic nephropathy indication. Ertugliflozin's glycemic efficacy diminishes below eGFR 45 and the label contraindicates initiation below 30 16.

Continuing Therapy as eGFR Declines

A common clinical question: should you stop the SGLT2 inhibitor when eGFR drops below the initiation threshold? The DAPA-CKD and EMPA-KIDNEY protocols permitted continuation to dialysis or eGFR <15. The 2024 ADA Standards of Care and KDIGO guidelines both support continuing an SGLT2 inhibitor once started, even as eGFR falls below the initiation threshold, as long as the drug is tolerated 7. The glycemic effect fades, but the cardiorenal protection persists.

Dr. Hiddo Lambers Heerspink, principal investigator of DAPA-CKD, stated: "The kidney-protective effects of SGLT2 inhibitors appear to be independent of their glucose-lowering action, which means stopping these drugs solely because eGFR drops below 30 would deprive patients of a proven renal benefit" 10.

Cost, Formulary Position, and Access

Brand-name SGLT2 inhibitors carry wholesale acquisition costs between $500 and $600 per month in the United States. No generic SGLT2 inhibitor is currently available as of mid-2026, though empagliflozin and dapagliflozin face near-term patent expirations.

Insurance Tier Placement

Most commercial plans place empagliflozin and dapagliflozin on preferred branded tiers (Tier 2 or 3) given their broad indication sets. Canagliflozin often falls to a non-preferred tier. Ertugliflozin has faced formulary exclusion from several large PBMs. Sotagliflozin, as a newer entrant, frequently requires prior authorization demonstrating concurrent T2DM and HF.

Medicare Part D Considerations

Under the Inflation Reduction Act, the $2,000 annual out-of-pocket cap (effective 2025) has reduced the financial barrier for Medicare beneficiaries on SGLT2 inhibitors. Prescribers should still verify formulary coverage, as some Part D plans prefer one agent over another.

Combination Therapy Considerations

SGLT2 inhibitors are frequently combined with metformin, GLP-1 receptor agonists, insulin, and DPP-4 inhibitors. The choice of SGLT2 agent does not typically change based on background therapy, with one exception.

SGLT2 Inhibitors Plus GLP-1 Receptor Agonists

The 2024 ADA consensus algorithm positions SGLT2 inhibitors and GLP-1 receptor agonists as complementary, not redundant 7. The DURATION-8 trial and multiple real-world analyses show additive A1C reduction of 0.5% to 0.7% and additive weight loss when combining these classes. For patients with T2DM, atherosclerotic CVD, and HFrEF, dual therapy with a GLP-1 RA (such as semaglutide) and an SGLT2 inhibitor (such as empagliflozin or dapagliflozin) addresses both macrovascular and HF risk 17.

With Insulin: Watch for eDKA

SGLT2 inhibitors combined with insulin require awareness of euglycemic DKA risk. This risk is higher in patients with lower beta-cell reserve, those on reduced insulin doses, or during perioperative periods. The Endocrine Society recommends holding SGLT2 inhibitors 3 to 4 days before planned surgery 18. This applies equally to all agents in the class.

A Practical Selection Algorithm

When the primary indication is HF (any ejection fraction), choose empagliflozin or dapagliflozin. Both have data across the full ejection fraction range. If the patient also has T2DM, sotagliflozin becomes a reasonable alternative, particularly after a recent HF hospitalization.

When the primary indication is CKD, choose dapagliflozin or empagliflozin. Dapagliflozin has the most mature data for CKD without diabetes (DAPA-CKD included 32.5% non-diabetic patients). Canagliflozin remains an option for diabetic nephropathy specifically, but its amputation and fracture signals limit enthusiasm.

When the primary indication is glycemic control alone, any agent works. Let formulary coverage and cost guide the pick. Ertugliflozin and bexagliflozin are clinically active but lack the outcome data that make empagliflozin and dapagliflozin first-line choices.

The 2022 AHA/ACC/HFSA Heart Failure Guideline gives SGLT2 inhibitors a Class I recommendation for HFrEF and a Class IIa for HFpEF, specifying dapagliflozin and empagliflozin by name: "In patients with HFrEF, SGLT2i [dapagliflozin or empagliflozin] are recommended to reduce hospitalization for HF and cardiovascular mortality" 19.

Monitor serum creatinine, potassium, and volume status 2 to 4 weeks after initiation, then every 3 to 6 months. Expect an initial eGFR dip of 3 to 5 mL/min/1.73 m² that stabilizes by week 4 to 6 and reflects hemodynamic changes in intraglomerular pressure, not structural injury 11.